Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Minerva Ginecologica 2020 October;72(5) > Minerva Ginecologica 2020 October;72(5):285-91

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Ginecologica 2020 October;72(5):285-91

DOI: 10.23736/S0026-4784.20.04615-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Effectiveness of the integration of quercetin, turmeric, and N-acetylcysteine in reducing inflammation and pain associated with endometriosis. In-vitro and in-vivo studies

Mario FADIN 1, Maria C. NICOLETTI 2, Marzia PELLIZZATO 3, Manuela ACCARDI 1, Maria G. BAIETTI 1, Andrea FRATTER 3

1 Private practitioner, Sempione Medical Center, Milan, Italy; 2 Pharm. D, Krea Innovazione srl, Milan, Italy; 3 Italian Society of Nutraceutical Formulators, Castelfranco Veneto, Treviso, Italy



BACKGROUND: to evaluate the efficacy of oral administration of a novel composition composed of quercetin, curcumin, acetylcysteine in reducing pain in women affected by endometriosis, through the reduction of the inflammatory-hyperproliferative component of the ectopic endometrial tissue.
METHODS: Thirty-three women with clinical diagnosis of endometriosis from at least 3 months have been enrolled. Patients have been treated daily with 200 mg of quercetin, 210 mg of dry extract of Curcuma longa (titrated at 95% in curcuminoids) and 150 mg of acetylcysteine (1 tablet of ALLIENDO®) for 2 months. The overall symptomatology with specific reference to dysmenorrhea, pelvic pain and dyspareunia, together with the frequency of nonsteroidal anti-inflammatory drugs (NSAID) drugs assumption have been evaluated at the beginning and at the end of the treatment.
RESULTS: Overall, the results collected at the end of the treatment according to the parameters evaluated and above mentioned on the 33 patients enrolled, show a significative improvement in the reduction of pain symptoms associated to endometriosis (P<0.001 for dysmenorrhea, pelvic pain and dyspareunia). The use of NSAIDs together with an overall reduction of their dosage and time of assumption has been reduced as well. No significative side effects have been observed.
CONCLUSIONS: The aforementioned results suggest that administration of the composition described can represent a valuable adjuvant treatment in the reduction of pain symptomatology associated to endometriosis, triggered by inflammatory cascade and hyperproliferation of ectopic tissue.


KEY WORDS: Endometriosis; Quercetin; Curcumin; Acetylcysteine

top of page